

Brief Articles

Structure–Activity Relationship Studies on *N'*-Aryl Carbohydrazide P2X₇ Antagonists

Derek W. Nelson,^{*,†} Kathy Sarris,[‡] Douglas M. Kalvin,[‡] Marian T. Namovic,[†] George Grayson,[†] Diana L. Donnelly-Roberts,[†] Richard Harris,[†] Prisca Honore,[†] Michael F. Jarvis,[†] Connie R. Faltynek,[†] and William A. Carroll[†]

Abbott Laboratories, Neuroscience Research and Advanced Technology, Global Pharmaceutical Research and Development, Abbott Park, Illinois 60064-6101

Received December 5, 2007


N'-Aryl acyl hydrazides were identified as P2X₇ receptor antagonists. Structure–activity relationship (SAR) studies evaluated functional activity by monitoring calcium flux inhibition in cell lines expressing recombinant human and rat P2X₇ receptors. Selected analogs were assayed in vitro for their capacity to inhibit release of cytokine IL-1 β . Compounds with potent antagonist function were evaluated in vivo using the zymosan-induced peritonitis model. A representative compound effectively attenuated mechanical allodynia in a rat model of neuropathic pain.

Introduction

Recently, the physiology and pharmacology of the P2X family of ligand-gated ion channels have been studied extensively.^{1–7} The ATP-sensitive, homomeric subtype P2X₇ receptor has received considerable attention because it is localized on cells of hematopoietic origin, and recent data indicate a role in the onset and persistence of certain pain states.⁸ Specifically, the P2X₇ receptor is expressed on macrophages and epidermal Langerhans cells.⁹ In addition, P2X₇ receptors are expressed on microglia¹⁰ and astrocytes¹¹ in the central nervous, but expression on neurons remains uncertain.¹² Activation of P2X₇ by extracellular ATP leads to ion flux,¹³ caspase-1 activation,¹⁴ release of the cytokine IL-1 β ,^{15,16} p38 MAP kinase activation,¹⁷ and, ultimately, reversible cell membrane pore formation that may lead to lysis and cell death.⁴ P2X₇ receptor activation has also been linked to glutamate release and inhibition of glutamate uptake.¹⁸ The impact of P2X₇ receptor activation on cytokines and glutamate regulation contributes to the mechanistic rationale for its role in the development and progression of several disease states or conditions including inflammation,¹⁹ neurodegeneration,²⁰ and neuropathic pain.^{8,21} The phenotype of P2X₇-knockout mice, which showed reduction in symptom severity in an arthritis model and resistance to the development of inflammatory and neuropathic pain, is consistent with a significant role of P2X₇ in nociceptive signaling.²²

Several different classes of P2X₇ receptor antagonists have been identified,⁸ but many of the early antagonist structures lacked properties suitable for therapeutic use. Efforts from our laboratories have focused on the development of small-molecule P2X₇ receptor antagonists for the treatment of pain. Two structurally distinct classes of potent and selective P2X₇ receptor antagonists have been disclosed previously. The disubstituted tetrazole **1**²³ and cyanoguanidine-containing structure **2**²⁴ represent selective, reversible P2X₇ antagonists that competitively

block the ATP binding site. Compound **1** inhibited Bz-ATP-stimulated IL-1 β release in human THP-1 cells and effectively reversed mechanical allodynia in the Chung model of neuropathic pain.



Our program has identified other distinct structures that function as P2X₇ receptor antagonists. A high-throughput screen (HTS) of the Abbott corporate compound library revealed the terpene-derived acyl hydrazide **3** as a novel P2X₇ antagonist, as measured by the inhibition of calcium flux (hP2X₇ pIC₅₀ = 7.3, rP2X₇ pIC₅₀ = 7.3). Herein, we describe the SAR studies around analogs of **3** that identified key substitutions influencing P2X₇ functional potency for this pharmacophore. An example from the new series of P2X₇ receptor antagonists exhibited efficacy in a behavioral model of neuropathic pain as well as a model of induced peritonitis.


Chemistry

The acyl hydrazide core of structure **3** differs from other reported pharmacophores that serve as P2X₇ receptor antagonists and presents new opportunities to probe the structural requirements for receptor activation.²⁵ The SAR studies involved manipulation of three different moieties within the acyl hydrazide pharmacophore: the aryl system bound to the terminal hydrazide nitrogen, the groups substituted on the nitrogen atoms, and the lipophilic acyl substituent. Synthesis of the acyl hydrazide compounds was accomplished by three different routes as shown in Scheme 1. Treatment of an aryl hydrazine or the corresponding hydrochloride salt with an acyl chloride in the presence of triethylamine generated the acyl hydrazides (route 1). Alternately, the aryl hydrazines coupled with carboxylic acids using tetramethylbenzotriazole uronium tetrafluoroborate (TBTU) in the presence of triethyl amine (route 2).²⁶ Selected libraries of acyl hydrazides were prepared by the high throughput organic synthesis (HTOS) group using microwave-

* To whom correspondence should be addressed. Abbott Laboratories, Neuroscience Research, R47W, AP10, 100 Abbott Park Road, Abbott Park, Illinois 60064-6101. Tel.: (847)-937-9825. Fax: (847)-935-5466. E-mail: derek.nelson@abbott.com.

[†] Neuroscience Research.

[‡] Advanced Technology.

Scheme 1^a

^a Reagents and conditions: (a) NEt₃, THF, rt; (b) TBTU, NEt₃, MeCN, rt or carbodiimide resin, HOBt, microwave; (c) NaNO₂, aq. HCl; (d) SnCl₂/2H₂O.

assisted coupling reactions between aryl hydrazine salts and carboxylic acids using resin-bound carbodiimide reagents (route 3).²⁷

Several aryl hydrazines required for the present study were commercially available, but brief syntheses of selected hydrazines were necessary. The quinoline and isoquinoline hydrazines were prepared by literature methods involving generation of a diazonium salt from the corresponding aminoquinoline derivative followed by reduction using tin(II) chloride.²⁸ For the chlorinated quinoline hydrazine required for the synthesis of **5h**, the 5-amino-2-chloroquinoline precursor was prepared by known procedures²⁹ and transformed into the hydrazinoquinoline as described above. The precursors of the lipophilic acyl substituents were commercially available as either the acid chlorides or the carboxylic acids.

Biology

In Vitro. Functional P2X₇ receptor activity was measured using two different methods: (1) inhibition of Ca²⁺ flux in cell lines expressing recombinant human or rat P2X₇ receptor, and (2) inhibition of IL-1 β release in differentiated THP-1 cells. Inhibition of Ca²⁺ flux was measured with a Fluorometric Imaging Plate Reader (FLIPR) using Fluo-4 as the calcium sensing dye and benzoylbenzoylATP (BzATP) as the agonist.³⁰ The FLIPR experiments utilized a 5 min pretreatment with the antagonist. Previous work has demonstrated that increased pretreatment times of 15, 30, and 60 min resulted in no change in the measured IC₅₀ values.²³ Recombinant human and rat P2X₇ were functionally expressed in stably transfected human 1321N1 astrocytoma cells devoid of endogenous P2X receptor function. An assay for inhibition of IL-1 β release was established in human THP-1 cells that had been differentiated with LPS and IFN γ then stimulated with BzATP for 30 min in the presence of test compounds.³¹ Measurement of IL-1 β release was performed using commercially available ELISA kits.

In Vivo. The in vivo efficacy of the novel P2X₇ antagonists in the acyl hydrazide series was evaluated in two different animal models. A model of zymosan-induced peritonitis determined compound-dependent modulation of cytokines including interleukin-1 (IL-1 β) in rats.³² In these experiments, acyl hydrazides were administered intraperitoneally or subcutaneously 30 min prior to intraperitoneal administration of a saline suspension of 2 mg zymosan. Four hours later, the animals were euthanized by CO₂ inhalation and the peritoneal cavities lavaged (2 $\times$ 15 mL) with ice cold phosphate buffered saline (w/o Ca²⁺ and Mg²⁺) with 10 units heparin/mL. For cytokine determination, the samples were spun at 10000 $\times$ g in a refrigerated microfuge (4 $^{\circ}$ C). The supernatants were removed and frozen until IL-1 β levels were determined by ELISA techniques.

Reversal of neuropathic pain was evaluated using the L5/L6 spinal nerve tight ligation (SNL) model.³³ In these experiments,

Table 1. Functional Potency of Acyl Hydrazide P2X₇ Antagonists with Modified Acyl Groups

compd	R	hP2X ₇ Ca ²⁺ flux pIC ₅₀ ^{a,c}	rP2X ₇ Ca ²⁺ flux pIC ₅₀ ^{a,c}
4a	<i>n</i> -hexyl	6.39 $\pm$ 0.05	6.71 $\pm$ 0.06
4b	<i>iso</i> -pentyl	6.83 $\pm$ 0.07	6.47 $\pm$ 0.02
4c	cyclohexyl	6.76 $\pm$ 0.03	6.61 $\pm$ 0.17
4d	1-methylcyclohexyl	7.15 $\pm$ 0.02	6.83 $\pm$ 0.06
4e	cyclohexylmethyl	7.41 $\pm$ 0.04	6.82 $\pm$ 0.01
4f	cyclopentyl	7.47 $\pm$ 0.07 ^b	7.31 $\pm$ 0.03 ^b
4g	1-phenylcyclopentyl	6.88 $\pm$ 0.02	6.82 $\pm$ 0.02
4h	1-adamantyl	7.93 $\pm$ 0.01 ^b	7.55 $\pm$ 0.09 ^b

^a Number of determinations = 2, unless otherwise indicated. ^b Number of determinations $\geq$ 3. ^c Standard error of measurement shown.

spinal nerve ligation was performed 7–14 days prior to the behavioral test. Mechanical allodynia was evaluated using von Frey monofilaments. Rats were tested before compound administration. Rats with paw withdrawal threshold <5 g were kept for compound testing. Rats were then tested again, 30 min following intraperitoneal administration of the P₂X₇ antagonist.


Result and Discussion

The initial structure–activity relationship studies of the acyl hydrazide compounds evaluated the spatial requirements for the lipophilic acyl moiety. Compounds containing acyclic and cyclic alkyl groups of varying size and flexibility indicated trends in the functional potency as measured by the FLIPR calcium flux assay (Table 1). Potency improved as larger, more rigid alkyl groups were incorporated. Cycloalkyl groups containing rings of 6–7 carbon atoms generated antagonists with comparable potency at both the human and rat receptors. Two of the acyl substitution patterns, specifically the benzylic groups with the spirocyclopentane moiety in the benzylic position (**4g**) and the adamantyl group (**4h**), afforded opportunities for rapid exploration and optimization of the structural properties. In addition, the rigid, three-dimensional adamantyl ring system distinguished the acyl hydrazides from the structures of the other antagonists under investigation in our laboratories.³⁴

Following the survey of acyl substituents that could replace the terpene-derived moiety in **3**, attention focused on the aryl portion of the pharmacophore. In the next cycle of SAR investigations, the acyl moiety was maintained as the adamantyl group while the aryl group was modified. The data are summarized in Table 2. For *N'*-phenyl hydrazides, substitution at the *ortho* position of the phenyl ring resulted in more potent antagonists (**5d**, **5g**, **5h**). Compounds with simple aromatic heterocycles bound to the terminal nitrogen of the hydrazide as exemplified by the *N'*-pyridyl hydrazides (**5j**, **5k**) afforded P2X₇ receptor antagonists with only modest potency. However, the *N'*-(5-isoquinolynyl) (**5l**) and *N'*-(5-quinolynyl)hydrazides (**5m**) proved more potent. The quinolynyl hydrazide also represented a core structure with more desirable physicochemical properties and additional opportunities for SAR explorations.


The third iteration of SAR studies employed the *N'*-5-quinolynyl moiety in conjunction with a selection of cyclic acyl moieties. Compounds **6a–e** evaluated the impact of modifications to the adamantyl ring system (Table 3). Contraction to the noradamantyl moiety (**6a**) caused a decrease in functional potency at the human receptor that eliminated some of the species discrepancy observed for adamantyl analog **5m**. Insertion of a methylene spacer between the adamantyl group and the carbonyl

Table 2. Functional Potency of Acyl Hydrazide P2X₇ Antagonists with Modified Aryl Groups

			
compd	Ar	hP2X ₇ Ca ²⁺ flux pIC ₅₀ ^{a,c}	rP2X ₇ Ca ²⁺ flux pIC ₅₀ ^{a,c}
5a	4-methoxyphenyl	6.01 ± 0.04	5.61 ± 0.03
5b	2,5-dimethylphenyl	7.24 ± 0.06	6.87 ± 0.03
5c	phenyl	6.96 ± 0.05 ^b	6.56 ± 0.07 ^b
5d	2-fluorophenyl	7.40 ± 0.08 ^b	6.69 ± 0.01 ^b
5e	3-fluorophenyl	6.49 ± 0.20	6.33 ± 0.10
5f	4-fluorophenyl	6.55 ± 0.19 ^b	5.97 ± 0.15 ^b
5g	2-chlorophenyl	7.94 ± 0.07 ^b	7.47 ± 0.04 ^b
5h	2,3-dichlorophenyl	7.46 ± 0.05 ^b	7.29 ± 0.06 ^b
5i	2,4-dichlorophenyl	6.43 ± 0.27	>5
5j	2-pyridyl	6.66 ± 0.05 ^b	6.37 ± 0.02
5k	3-pyridyl	6.08 ± 0.02	6.01 ± 0.09
5l	5-isoquinolyl	7.47 ± 0.07 ^b	6.82 ± 0.08 ^b
5m	5-quinolyl	7.99 ± 0.05 ^b	7.35 ± 0.06 ^b
5h	2-chloro-5-quinolyl	7.29 ± 0.14 ^b	6.76 ± 0.01

^a Number of determinations = 2, unless otherwise indicated. ^b Number of determinations ≥ 3. ^c Standard error of measurement shown.

Table 3. Functional Potency of Quinoline Derived Acyl Hydrazide P2X₇ Antagonists

			
compd	R ¹	hP2X ₇ Ca ²⁺ flux pIC ₅₀ ^{a,c}	rP2X ₇ Ca ²⁺ flux pIC ₅₀ ^{a,c}
6a	3-noradamantyl	7.56 ± 0.08 ^b	7.28 ± 0.08 ^b
6b	1-adamantylmethyl	7.24 ± 0.01	6.22 ± 0.02 ^b
6c	3-chloro-1-adamantyl	7.99 ± 0.04 ^b	7.45 ± 0.06 ^b
6d	3-ethyl-1-adamantyl	7.64 ± 0.17	6.84 ± 0.07
6e	3-hydroxy-1-adamantyl	6.56 ± 0.0.09	5.65 ± 0.07
6f	1-(4-methoxyphenyl)cyclohexyl	7.28 ± 0.04 ^b	7.29 ± 0.10 ^b
6g	1-(2-fluorophenyl)cyclohexyl	6.72 ± 0.06	6.49 ± 0.07 ^b
6h	1-(3-fluorophenyl)cyclohexyl	6.85 ± 0.10 ^b	6.59 ± 0.17 ^b
6i	1-(4-fluorophenyl)cyclohexyl	7.15 ± 0.09 ^b	6.76 ± 0.02 ^b
6j	2,2,3,3-tetramethylcyclopropyl	6.70 ± 0.11 ^b	6.81 ± 0.04
6k	1,2,2,3-tetramethylcyclopentyl	7.56 ± 0.06 ^b	6.91 ± 0.02 ^b
6l	2-methyl-5-norbornen-2-yl	7.73 ± 0.12 ^b	7.50 ± 0.08 ^b
6m	7,7-dimethyl-2-oxonorborn-1-yl	5.86 ± 0.03	5.82 ± 0.13

^a Number of determinations = 2, unless otherwise indicated. ^b Number of determinations ≥ 3. ^c Standard error of measurement shown.


group in analog **6b** decreased functional potency. Halogen and alkyl substituents at the C(3) bridgehead of the adamantyl system (**6c**, **6d**) caused little change in antagonist potency, but the hydroxyl group was not well tolerated (**6e**). Compounds **6f–i** evaluated the influence of electron-donating and electron-withdrawing groups on the phenyl ring of the spirocyclic benzylic groups. The fluoro group was tolerated at the *ortho*, *meta*, and *para* positions, but the 4-methoxyphenyl substitution pattern of **6f** provided the greatest potency. Derivative **6f** also demonstrated comparable functional potency at both the human and rat receptors. Alternate lipophilic acyl moieties were also explored, and antagonist function was retained for a range of differently substituted cycloalkyl and polycyclic hydrocarbon groups (**6j–6m**).

Selected acyl hydrazide antagonists were evaluated for their capacity to inhibit IL-1 β release in vitro using human THP-1 cells (Table 4). The *N*-quinoline acyl hydrazide **5m** inhibited IL-1 β release efficiently, and the pIC₅₀ value for IL-1 β inhibition was comparable to the potency in the FLIPR assay. Compound **6c** was highly potent in the in vitro assay for inhibition of IL-1 β release, and the IC₅₀ was below the detection

Table 4. Functional Potency of Acyl Hydrazide P2X₇ Antagonists in the Inhibition of Human IL-1 β Release In Vitro and Efficacy In Vivo in the Zymosan Model

compd (A-number)	hIL-1 β release pIC ₅₀ ^{a,b}	zymosan (i.p.; % effect at 20 μ mol/kg) ^a
5m	8.3 ± 0.2	63
6a	6.8 ± 0.1	55
6c	>9.0	49
5g	NT ^c	63
4h	NT	66

^a Number of determinations = 3, unless otherwise indicated. ^b Standard error of measurement shown. ^c NT = not tested.

**Figure 1.** Effects of **5m** on mechanical allodynia observed in the SNL model of neuropathic pain.**Table 5.** Pharmacokinetic Profile of **5m** in Rats^a

route	V β (L/kg)	Cl _p (L/hr·kg)	C _{max} (μ g/mL)	T _{max} (hr)	AUC (μ g·hr/L)	t _{1/2} (hr)	F (%)
IV	0.90	1.7			0.94	0.40	
IP			0.44	0.50	0.39	0.60	42

^a All animals administered doses of 5 μ mol/kg in 10% DMSO/90%PEG.

limit of the assay. Selected acyl hydrazides were also evaluated using an in vivo model of zymosan-induced peritonitis in which inhibition of production IL-1 β was measured directly. Prophylactic administration of selected acyl hydrazide P2X₇ receptor antagonists caused a substantial inhibition of IL-1 β release. Intraperitoneal administration of 20 mmol/kg of the acyl hydrazides **5m**, **5g**, and **4h** produced >60% reduction in IL-1 β release.

Previous work with other classes of P2X₇ receptor antagonists demonstrated a correlation between inhibition of IL-1 β release and efficacy in behavioral models of neuropathic pain,²⁴ although a mechanistic rationale for this relationship was not established. Behavioral effects of compound **5m** were evaluated in the spinal nerve ligation (SNL) model of neuropathic pain. Intraperitoneal (ip) administration of **5m** (30–300 μ mol/kg) resulted in a dose-related reversal of mechanical allodynia on the injured (ipsilateral) side with an ED₅₀ value of 92 μ mol/kg and a maximum response of 68% relative to the noninjured (contralateral) side (Figure 1). The pharmacokinetic parameters of **5m** (Table 5) indicate plasma exposure levels consistent with the observed behavioral effects.

The above results demonstrate the potential of the acyl hydrazide pharmacophore to reduce pain transmission and cytokine production. The efficacy of **5m** in the SNL model of neuropathic pain (Figure 1) is consistent with previous reports of antinociception using other structurally distinct P2X₇ antagonists.²⁴ The mechanistic basis for the analgesic effects has not been determined, but compound **5m** was found to have no significant interactions for concentrations up to 10 μ M at other P2 receptors (P2X₃, P2X₄, and P2Y₂). In addition, a screen of compound **5g** against a variety of over 70 other receptors, enzymes, and ion channels revealed no substantial interactions using a concentration of 10 μ M.

Conclusion

We have identified a novel series of acyl hydrazide P2X₇ receptor antagonists. Examples of this new pharmacophore exhibited functional potency using in vitro assays that monitor distinct steps along the cascade initiated by P2X₇ receptor activation. The SAR studies conducted in this work revealed preferred substitution patterns for the N' and acyl termini of the hydrazide structure. For the N'-aryl moiety, *ortho*-substituted phenyl groups produced potent P2X₇ receptor antagonists, as did 5-substituted quinoline ring systems. Replacement of the N-H bonds in the hydrazide was not tolerated. In the acyl moiety, rigid polycyclic hydrocarbon ring systems exemplified by the adamantyl group generated potent antagonist function. Similarly, acyl groups derived from 1-phenylcyclohexanecarboxylic acid imparted a favorable balance of potency and physicochemical properties. The primary in vitro FLIPR assay utilized in this study revealed minor discrepancies between functional potency at the recombinant human and rat receptors, but certain substitution patterns minimized the differences. Finally, compound **5m** was found to possess antinociceptive efficacy in a model of neuropathic pain, providing additional evidence for the potential of the P2X₇ receptor as a molecular target for pain. Compound **5m** also reduced the release of the inflammatory cytokine IL-1 β in a zymosan-induced model of peritonitis demonstrating that P2X₇ receptor antagonists can inhibit inflammatory pathways.

Supporting Information Available: Synthetic procedures and characterization data for intermediates and final products. Complete descriptions of biological protocols. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- (1) North, R. A.; Barnard, E. A. Nucleotide receptors. *Curr. Opin. Neurobiol.* **1997**, *7*, 346–357.
- (2) Ralevic, V.; Burnstock, G. Receptors for purines and pyrimidines. *Pharmacol. Rev.* **1998**, *50*, 413–492.
- (3) Jacobsen, K. A.; Jarvis, M. F.; Williams, M. Purine and pyrimidine (P2) receptors as drug targets. *J. Med. Chem.* **2002**, *45*, 4057–4093.
- (4) North, R. A. Molecular physiology of P2X receptors. *Physiol. Rev.* **2002**, *82*, 1013–1067.
- (5) Burnstock, G. Pathophysiology and therapeutic potential of purinergic signaling. *Pharmacol. Rev.* **2006**, *58*, 58–78.
- (6) Geiger, J. R.; Cockayne, D. A.; Dillon, M. P.; Burnstock, G.; Ford, A. P. D. W. Pharmacology of P2X channels. *Eur. J. Physiol.* **2006**, *452*, 513–537.
- (7) Khakh, B. S.; North, R. A. P2X receptors as cell-surface ATP sensors in health and disease. *Nature* **2006**, *442*, 527–532.
- (8) (a) Donnelly-Roberts, D. L.; Jarvis, M. F. Discovery of P2X₇ receptor selective antagonists offers new insights into P2X₇ receptor function and indicates a role in chronic pain states. *Br. J. Pharmacol.* **2007**, *151*, 571–579. (b) Gunosewoyo, H.; Coster, M. J.; Kassiou, M. Molecular probes for P2X₇ receptor studies. *Curr. Med. Chem.* **2007**, *14*, 1505–1523.
- (9) Surprenant, A.; Rassendren, F.; Kawashima, E.; North, R. A.; Buell, G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X (P2X₇) receptor. *Science* **1996**, *272*, 735–738.
- (10) Ferrari, D.; Villalba, M.; Chiozzi, P.; Falzoni, S.; Ricciardi-Castagnoli, P.; DiVirgilio, F. Mouse microglia cells express a plasma membrane pore gated by extracellular ATP. *J. Immunol.* **1996**, *156*, 1531–1539.
- (11) (a) Irnich, D.; Burgstahler, R.; Grafe, P. P2 nucleotide receptors in peripheral nerve trunk. *Drug Dev. Res.* **2001**, *52*, 83–88. (b) Ballerini, P.; Rathbone, M. P.; Di Iorio, P.; Renzetti, A.; Giuliani, P.; D'Alimonte, I.; Trubiani, O.; Caciagli, F.; Ciccarelli, R. Rat astroglial P2Z (P2X₇) receptors regulate intracellular calcium and purine release. *NeuroReport* **1996**, *7*, 2533–2537.
- (12) (a) Deuchars, S. A.; Atkinson, L.; Brooke, R. E.; Musa, H.; Milligan, C. J.; Batten, T. F. C.; Buckley, N. J.; Parson, S. H.; Deuchars, J. Neuronal P2X₇ receptors are targeted to presynaptic terminals in the central and peripheral nervous system. *J. Neurosci.* **2001**, *21*, 7143–7152. (b) Sim, J. A.; Young, M. T.; Sung, H.-Y.; North, R. A.; Surprenant, A. Reanalysis of P2X₇ receptor expression in rodent brain. *J. Neurosci.* **2004**, *24*, 6307–6314. (c) Anderson, C. M.; Nedergaard, M. Emerging challenges of assigning P2X(7) receptor function and immunoreactivity in neurons. *Trends Neurosci.* **2006**, *29*, 257–262.
- (13) Buisman, H. P.; Steinberg, T. H.; Fischbarg, J.; Silverstein, S. C.; Vogelzang, S. A.; Ince, C.; Ypey, D. L.; Leijh, P. C. Extracellular ATP induces a large nonselective conductance in macrophage plasma membranes. *Proc. Natl. Acad. Sci. U.S.A.* **1988**, *85*, 7988–7992.
- (14) Kahlenberg, J. M.; Dubyak, G. W. Mechanisms of caspase-1 activation by P2X₇ receptor-mediated K⁺ release. *Am. J. Cell Physiol.* **2004**, *286*, C1100–C1108.
- (15) Perregaux, D.; Gabel, C. A. Interleukin-1 β maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. *J. Biol. Chem.* **1994**, *269*, 15195–15203.
- (16) Walev, I.; Klein, J.; Husmann, M.; Valeva, A.; Strauch, S.; Wittz, H.; Weichel, O.; Bhakdi, S. Potassium inhibited processing of IL-1 β in human monocytes. *EMBO J.* **1995**, *14*, 1607–1614.
- (17) Donnelly-Roberts, D. L.; Namovic, M.; Faltynek, C. R.; Jarvis, M. F. Mitogen-activated protein kinase and caspase signaling pathways are required for P2X₇ receptor (P2X₇R)-induced pore formation in human THP-1 cells. *J. Pharmacol. Exp. Ther.* **2004**, *308*, 1053–1061.
- (18) (a) Papp, L.; Vizi, E. S.; Sperl gh, B. Lack of ATP-evoked GABA and glutamate release in the hippocampus of P2X₇ receptor-/- mice. *NeuroReport* **2004**, *15*, 2387–2391. (b) Duan, S.; Anderson, C. M.; Keung, E. C.; Chen, Y.; Chen, Y.; Swanson, R. A. P2X₇ receptor-mediated release of excitatory amino acids from astrocytes. *J. Neurosci.* **2003**, *23*, 1320–1328.
- (19) (a) DiVirgilio, F.; Vishwanath, V.; Ferrari, D. On the role of the P2X₇ receptor in the immune system. *Handbook Exp. Pharmacol.* **2001**, *151*, 355–374. (b) DiVirgilio, F.; Falzoni, S.; Mutini, C.; Sanz, J. M.; Chiozzi, P. Purinergic P2X₇ receptor: A pivotal role in inflammation and immunomodulation. *Drug. Dev. Res.* **1998**, *45*, 207–213.
- (20) (a) LeFeuvre, R. A.; Brough, D.; Touzani, O.; Rothwell, N. J. Role of P2X₇ receptors in ischemic and excitotoxic brain injury in vivo. *J. Cereb. Blood Flow Metab.* **2003**, *23*, 381–384. (b) LeFeuvre, R.; Brough, D.; Rothwell, N. Extracellular ATP and P2X₇ receptors in neurodegeneration. *Eur. J. Pharmacol.* **2002**, *447*, 261–269. (c) Rampe, D.; Wang, L.; Ringheim, G. E. P2X₇ receptor modulation of β -amyloid- and LPS-induced cytokine secretion from human macrophages and microglia. *J. Neuroimmunol.* **2004**, *147*, 56–61. (d) Wang, X.; Arcuino, G.; Takano, T.; Lin, J.; Peng, W. G.; Wan, P.; Li, P.; Xu, Q.; Liu, Q. S.; Goldman, S. A.; Nedergaard, M. P2X₇ receptor inhibition improves recovery after spinal cord injury. *Nature Med.* **2004**, *10*, 821–827.
- (21) (a) Raghavendra, V.; DeLeo, J. A. The role of astrocytes and microglia in persistent pain. *Adv. Mol. Cell Biol.* **2004**, *31*, 951–966. (b) Milligan, E. D.; Maier, S. F.; Watkins, L. R. Review: Neuronal-glial interactions in central sensitization. *Semin. Pain Med.* **2003**, *1*, 171–183.
- (22) (a) Labasi, J. M.; Petrushova, N.; Donovan, C.; McCurdy, S.; Lira, P.; Payette, M. M.; Brissette, W.; Wicks, J. R.; Audoly, L.; Gabel, C. A. Absence of the P2X₇ receptor alters leukocyte function and attenuates an inflammatory response. *J. Immunol.* **2002**, *168*, 6436–6445. (b) Chessell, I. P.; Hatcher, J. P.; Bountra, C.; Michel, A. D.; Hughes, J. P.; Green, P.; Egerton, J.; Murfin, M.; Richardson, J.; Peck, W. L.; Grahames, C. B. A.; Casula, M. A.; Yiangou, Y.; Birch, R.; Anand, P.; Buell, G. N. Disruption of the P2X₇ purinoceptor gene abolishes chronic inflammatory and neuropathic pain. *Pain* **2005**, *114*, 386–396.
- (23) (a) Nelson, D. W.; Gregg, R. J.; Kort, M. E.; Perez-Medrano, A.; Voight, E. A.; Wang, Y.; Namovic, M. T.; Grayson, G.; Donnelly-Roberts, D. L.; Niforatos, W.; Honore, P.; Jarvis, M. F.; Faltynek, C. R.; Carroll, W. A. Structure–activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X₇ antagonists. *J. Med. Chem.* **2006**, *49*, 3659–3666. (b) Examples of triazole derivatives of the tetrazole pharmacophore have also been disclosed: Carroll, W. A.; Kalvin, D. M.; Perez-Medrano, A.; Florjancic, A. S.; Wang, Y.; Donnelly-Roberts, D. L.; Namovic, M. T.; Grayson, G.; Honor , P.; Jarvis, M. F. Novel and potent 3-(2,3-dichlorophenyl)-4-

- (benzyl)-4H-1,2,4-triazole P2X₇ antagonists. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 4044–4048. (c) Florjancic, A. S.; Peddi, S.; Perez-Medrano, A.; Li, B.; Namovic, M. T.; Grayson, G.; Donnelly-Roberts, D. L.; Jarvis, M. F.; Carroll, W. A. Synthesis and in vitro activity of 1-(2,3-dichlorophenyl)-N-(pyridin-3-ylmethyl)-4H-1,2,4-triazol-3-amine P2X₇ antagonists. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 2089–2092.
- (24) (a) Honore, P. M.; Donnelly-Roberts, D. L.; Namovic, M.; Hsieh, G.; Zhu, C.; Mikusa, J.; Hernandez, G.; Zhong, C.; Gauvin, D.; Chandran, P.; Harris, R.; Perez-Medrano, A.; Carroll, W. A.; Marsh, K.; Sullivan, J.; Faltynek, C. R.; Jarvis, M. F. A-740003 (*N*-(1-[(cyanoimino)(5-quinolinylamino)methyl]amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide, a novel and selective P2X₇ receptor antagonist dose-dependently reduces neuropathic pain in the rat. *J. Pharmacol. Exp. Ther.* **2006**, *319*, 1376–1385. (b) Perez-Medrano, A.; Donnelly-Roberts, D. L.; Faltynek, C. R.; Honore, P.; Jarvis, M. F.; Peddi, S.; Wang, Y.; Carroll, W. A. Discovery and biological evaluation of novel cyanoguanidine P2X₇ antagonists for the treatment of neuropathic pain. *J. Med. Chem.* submitted for publication. (c) Morytko, M. J.; Betschmann, P.; Woller, K.; Ericsson, A.; Chen, H.; Donnelly-Roberts, D. L.; Namovic, M. T.; Jarvis, M. F.; Carroll, W. A.; Rafferty, P. R. Synthesis and in vitro activity of *N*-cyano-4-(2-phenylacetyl)-*N*-octylpiperazine-1-carboxamide P2X₇ antagonists. *Biorg. Med. Chem. Lett.* **2008**, *18*, 2093–2096.
- (25) Structures derived from adamantane amides were investigated independently by AstraZeneca: Alcaraz, L.; Furber, M.; Nortimer, M. Adamantane derivatives. WO 00/61569, 2000.
- (26) Knorr, R.; Trzeciak, A.; Bannwarth, W.; Gillesen, D. New coupling reagents in peptide chemistry. *Tetrahedron Lett.* **1989**, *30*, 1927–1930.
- (27) The details of the procedure are available in the Supporting Information.
- (28) Dionne, G.; Humber, L. G.; Asselin, A.; McQuillan, J.; Treasurywala, A. M. Ligand–receptor interaction via hydrogen-bond formation. Synthesis and pharmacological evaluation of pyrrolo and pyrido analogues of the cardiotonic agent 7-hydroxycyclindole. *J. Med. Chem.* **1986**, *29*, 1452–1457.
- (29) (a) Deinet, A. J.; Lutz, R. E. Antimalarials 2-chloro-5-(3-diethylaminopropylamino)-quinoline. Useful preparations of 2-chloro-5- and 9-nitroquinolines. *J. Am. Chem. Soc.* **1946**, *68*, 1325–1326. (b) Capps, J. D.; Hamilton, C. S. Syntheses in the quinoline series. I. 2-Hydroxy- and 2-chloroquinolinecarboxylic acids. *J. Am. Chem. Soc.* **1938**, *60*, 2104–2106.
- (30) Bianchi, B. R.; Lynch, K. J.; Touma, E.; Niforatos, W.; Burgard, E. C.; Alexander, K. M.; Park, H. S.; Yu, H.; Metzger, R.; Kowaluk, E. Pharmacological characterization of recombinant human and rat P2X₂ receptor subtypes. *Eur. J. Pharmacol.* **1999**, *376*, 127–138.
- (31) Donnelly-Roberts, D. L.; Namovic, M.; Faltynek, C. R.; Jarvis, M. F. Mitogen-activated protein kinase and caspase signaling pathways are required for P2X₇ receptor (P2X₇R)-induced pore formation in human THP-1 cells. *J. Pharmacol. Exp. Ther.* **2004**, *308*, 1053–1061.
- (32) (a) Perretti, M.; Solito, E.; Parente, L. Evidence that endogenous interleukin-1 is involved in leukocyte migration in acute experimental inflammation in rats and mice. *Agents Actions* **1992**, *35*, 71–78. (b) Torok, K.; Nemeth, K.; Erdo, F.; Aranyi, P.; Szekely, J. I. Measurement and drug induced modulation of interleukin-1 level during zymosan peritonitis in mice. *Inflammation Res.* **1995**, *44*, 248–252.
- (33) Jarvis, M. F.; Burgard, E. C.; McGaraughty, S.; Honore, P.; Lynch, K.; Brennan, T. J.; Subieta, A.; van Biesen, T.; Cartmell, J.; Bianchi, B.; Niforatos, W.; Kage, K.; Yu, H.; Mikusa, J.; Wismer, C. T.; Zhu, C. Z.; Chu, K.; Lee, C.-H.; Stewart, A. O.; Polakowski, J.; Cox, B. F.; Kowaluk, E.; Williams, M.; Sullivan, J.; Faltynek, C. A-317491, a novel potent and selective nonnucleotide antagonist of P2X₃ and P2X_{2/3} receptors, reduces chronic inflammatory and neuropathic pain in the rat. *Proc. Natl. Acad. Sci. U.S.A.* **2002**, *99*, 17179–17184.
- (34) (a) The adamantyl moiety has been employed in P2X₇ antagonists developed at other institutions. For an example, see: Baxter, A.; Bent, J.; Bowers, K.; Braddock, M.; Brough, S.; Fagura, M.; Lawson, M.; McNally, T.; Mortimer, M.; Robertson, M.; Weaver, R.; Webborn, P. Hit-to-lead studies: The discovery of potent adamantane amide P2X₇ receptor antagonists. *Bioorg. Med. Chem. Lett.* **2003**, *8*, 4047–4050. (b) Furber, M.; Alcaraz, L.; Bent, J. E.; Beyerbach, A.; Bowers, K.; Braddock, M.; Caffrey, M. V.; Cladingboel, D.; Collington, J.; Donald, D. K.; Fagura, M.; Ince, F.; Kinchin, E. C.; Laurent, C.; Lawson, M.; Luker, T. J.; Mortimore, M. M. P.; Pimm, A. D.; Riley, R. J.; Roberts, N.; Robertson, M.; Theaker, J.; Thorne, P. V.; Weaver, R.; Webborn, P.; Willis, P. Discovery of potent and selective adamantane-based small-molecule P2X₇ receptor antagonists/interleukin-1 inhibitors. *J. Med. Chem.* **2007**, *50*, 5882–5885.

JM701516F